Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Equity Average (2022 - 2025)

Atara Biotherapeutics' Equity Average history spans 4 years, with the latest figure at -$37.6 million for Q4 2025.

  • For Q4 2025, Equity Average rose 60.0% year-over-year to -$37.6 million; the TTM value through Dec 2025 reached -$37.6 million, up 60.0%, while the annual FY2025 figure was -$67.9 million, 7070.48% down from the prior year.
  • Equity Average reached -$37.6 million in Q4 2025 per ATRA's latest filing, down from -$35.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $240.9 million in Q2 2022 to a low of -$104.6 million in Q2 2024.
  • Average Equity Average over 4 years is $17.4 million, with a median of -$21.7 million recorded in 2023.
  • The largest YoY upside for Equity Average was 64.41% in 2025 against a maximum downside of 16606.5% in 2025.
  • A 4-year view of Equity Average shows it stood at $156.9 million in 2022, then plummeted by 84.58% to $24.2 million in 2023, then tumbled by 488.12% to -$93.9 million in 2024, then surged by 60.0% to -$37.6 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Equity Average are -$37.6 million (Q4 2025), -$35.8 million (Q3 2025), and -$45.1 million (Q2 2025).